What Werewolf Therapeutics, Inc. does.

We are an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. We are leveraging our proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our molecules, which we refer to as INDUKINE and INDUCER molecules, are intended to activate selectively in the tumor microenvironment, or TME. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12), respectively, INDUKINE molecules for the treatment of multiple tumor types.

We are also utilizing this PREDATOR platform know-how and expertise to develop conditionally activated immune cell engagers. Immune cell engagers, such as T cell engagers, are typically bispecific antibodies that redirect immune cells to cancer cells via engagement with tumor associated cell surface antigens, leading to immune cell mediated killing of the cancer cells. We have provided initial preclinical data for our proprietary INDUCER™ T cell engager molecules demonstrating that our PREDATOR masking technology silenced peripheral activity and prevented cytokine release.

Revenue and profit, by fiscal year.

More on HOWL.

• Werewolf Therapeutics, Inc. summary
• Werewolf Therapeutics, Inc. financial statements
• Werewolf Therapeutics, Inc. key metrics
• Werewolf Therapeutics, Inc. health scores and style box
• Werewolf Therapeutics, Inc. earnings
• Werewolf Therapeutics, Inc. dividends
• Werewolf Therapeutics, Inc. valuation
• Werewolf Therapeutics, Inc. ownership and insiders
• Werewolf Therapeutics, Inc. peers

Figures from Werewolf Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.